2011
DOI: 10.1007/978-1-4614-0323-4_10
|View full text |Cite
|
Sign up to set email alerts
|

Topoisomerase I Inhibitors: Chemical Biology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2012
2012
2014
2014

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 119 publications
0
4
0
Order By: Relevance
“…The wide range of in vivo tumor models like syngeneic, human tumor xenograft, orthotopic, metastatic, and genetically engineered mouse models is available from the basis of the compounds selected and treatments that go into clinical testing of patients [ 55 ]. The ability to exhibit anchorage-independent cell growth (colony-forming capacity in semisolid media) has been considered to be fundamental in cancer biology because it has been connected with tumor cell aggressiveness in vivo such as tumorigenic and metastatic potentials and also utilized as a marker for in vitro transformation.…”
Section: Anchorage-independent Tumor Model Systemmentioning
confidence: 99%
“…The wide range of in vivo tumor models like syngeneic, human tumor xenograft, orthotopic, metastatic, and genetically engineered mouse models is available from the basis of the compounds selected and treatments that go into clinical testing of patients [ 55 ]. The ability to exhibit anchorage-independent cell growth (colony-forming capacity in semisolid media) has been considered to be fundamental in cancer biology because it has been connected with tumor cell aggressiveness in vivo such as tumorigenic and metastatic potentials and also utilized as a marker for in vitro transformation.…”
Section: Anchorage-independent Tumor Model Systemmentioning
confidence: 99%
“…13 Likewise, the indolocarbazole class is a potential source of therapeutic Top1 inhibitors with advantages similar to the indenoisoquinoline class. 14 One exemplary indolocarbazole, the Top1 inhibitor edotecarin ( 7 ), advanced to a Phase III clinical trial, where it unfortunately failed. 15 …”
Section: Introductionmentioning
confidence: 99%
“…Out of hundreds of biologically evaluated indenoisoquinolines, indotecan (LMP400, 4 ) and indimitecan (LMP776, 5 ) were promoted to a Phase I clinical trial at the National Institutes of Health, which began in 2010 . Likewise, the indolocarbazole class is a potential source of therapeutic Top1 inhibitors with advantages similar to the indenoisoquinoline class . One exemplary indolocarbazole, the Top1 inhibitor edotecarin ( 7 ), advanced to a Phase III clinical trial, where it unfortunately failed …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation